Seufferlein Thomas, Michalski Christoph
Klinik für Innere Medizin I, Universitätsklinikum Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Deutschland.
Klinik für Allgemein- und Viszeralchirurgie, Universitätsklinikum Ulm, Ulm, Deutschland.
Chirurg. 2022 May;93(5):441-445. doi: 10.1007/s00104-022-01623-w. Epub 2022 Apr 4.
Pancreatic cancer still has a very unfavorable prognosis. This is true even for the comparably small group of patients (maximum 15%) who are diagnosed with a clearly resectable tumor. The article provides information on the current statements of the S3 guidelines on adjuvant and neoadjuvant treatment of resectable pancreatic cancer and describes adjuvant and neoadjuvant treatment strategies. Furthermore, the article pursues the questions of if and for whom a total neoadjuvant treatment is suitable and which options of a personalized treatment are available for resectable pancreatic cancer.
胰腺癌的预后仍然非常不理想。即使对于诊断为可明确切除肿瘤的相对较小的患者群体（最多15%）来说也是如此。本文提供了S3指南关于可切除胰腺癌辅助和新辅助治疗的当前声明信息，并描述了辅助和新辅助治疗策略。此外，本文探讨了全新辅助治疗是否适合以及适合哪些患者的问题，以及可切除胰腺癌有哪些个性化治疗选择。
